Livforsakringsbolaget Skandia Omsesidigt Buys 256 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Livforsakringsbolaget Skandia Omsesidigt lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 68.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 630 shares of the medical equipment provider’s stock after acquiring an additional 256 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Zimmer Biomet were worth $77,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Zimmer Biomet by 19.0% during the 1st quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider’s stock worth $2,954,843,000 after acquiring an additional 3,695,510 shares during the last quarter. American Century Companies Inc. raised its position in Zimmer Biomet by 21.2% in the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock worth $545,809,000 after purchasing an additional 852,186 shares during the period. Geode Capital Management LLC raised its position in Zimmer Biomet by 2.3% in the 1st quarter. Geode Capital Management LLC now owns 4,315,167 shares of the medical equipment provider’s stock worth $556,244,000 after purchasing an additional 96,028 shares during the period. Morgan Stanley raised its position in Zimmer Biomet by 80.5% in the 4th quarter. Morgan Stanley now owns 3,102,429 shares of the medical equipment provider’s stock worth $395,560,000 after purchasing an additional 1,384,068 shares during the period. Finally, Victory Capital Management Inc. raised its position in Zimmer Biomet by 4.9% in the 3rd quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider’s stock worth $345,690,000 after purchasing an additional 144,147 shares during the period. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Up 0.1 %

Shares of NYSE:ZBH opened at $119.43 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $149.25. The firm has a market capitalization of $24.54 billion, a P/E ratio of 24.42, a P/E/G ratio of 2.19 and a beta of 1.01. The stock has a 50 day moving average price of $126.33 and a 200-day moving average price of $119.16. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. During the same quarter in the prior year, the company earned $1.88 EPS. The business’s revenue was up 6.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Analysts Set New Price Targets

ZBH has been the topic of a number of analyst reports. Citigroup lifted their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Truist Financial lifted their target price on shares of Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research report on Friday, February 9th. Barclays lifted their target price on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research report on Monday, February 12th. JPMorgan Chase & Co. lifted their target price on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Finally, Raymond James boosted their price objective on shares of Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $139.39.

Insider Transactions at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.95% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.